Web Research

Web Research — RadNet (RDNT)

The Bottom Line from the Web

RadNet's investment thesis is no longer "outpatient imaging operator" — the web is overwhelmingly about an AI platform transformation that the filings only begin to capture. Two back-to-back acquisitions (iCAD in July 2025, Gleamer for up to €230M in March 2026) have positioned DeepHealth as "the world's largest radiology AI provider," and management just restructured the executive team in January 2026 in a way that reads like the beginning of a Berger succession plan after 38+ years. The other signal the internet surfaces and the filings do not: a Q3 2025 earnings quality warning (revenue beat, EPS missed by 65%) and a sharp re-rating since — shares are down from ~$73 in November 2025 to ~$57 on April 20, 2026, while analysts still carry a "Strong Buy" rating. The gap between price action and ratings is the single most important setup going into the Q1 2026 print.

What Matters Most

1. Gleamer acquisition for up to €230M — largest radiology AI consolidation to date

Announced concurrently with Q4 2025 earnings on March 2, 2026. Combined with the iCAD acquisition completed July 17, 2025 (all-stock), RadNet has spent ~$400M+ in AI M&A in nine months. Management's 2026 Digital Health guidance — 45–56% revenue growth — is predicated on these assets. Source: stocktitan SEC filing, tikr.com analysis.

2. Executive team restructured January 7, 2026 — reads like Berger succession planning

Specifically: Stephen Forthuber → President & CEO, Eastern Operations; Norman Hames → President & CEO, Western Operations; Mital Patel → EVP & Chief Operating Officer; Greg Sorensen, M.D. → expanded role from Chief Science Officer. Separately, Kees Wesdorp was appointed President/CEO of Digital Health in July 2025. Berger retains Chairman/CEO roles — but two regional CEO titles is a federated structure that could outlive him. Source: GlobeNewswire.

3. Q3 2025 EPS missed by 65% — an earnings-quality warning the filings bury

This is the cleanest single-finding case where web reporting adds what the press release doesn't surface. Full-year 2025 reinforced it: revenue +11.5% to $2,040.2M, adjusted EBITDA of $300.2M — but a GAAP net loss of $18.7M ($-0.25/share). Source: Simply Wall St article, stocktitan 8-K.

4. Sharp price re-rating — down ~22% from November highs into April 2026

The setup: 8 buy ratings, 0 hold/sell (directors talk, 2026-02-16). Price targets span $76.80 (stockanalysis.com median) to $93.58 (fintel average, range $86.86–$102.90). At $57, that implies 35–65% implied upside — but the chart says the market is pricing in reset expectations. Source: Markets Daily, fintel.

5. CEO Berger 2025 pay jumped 25% to $12.1M — filed April 20, 2026

Source: Quiver Quantitative CEO Pay Revealed. Combined-chair structure is explicitly defended in the 2026 proxy ("effectively utilizes Dr. Berger's knowledge"), but ISS Governance QualityScore is 6 of 10 (mid-range governance risk).

6. Insider selling concentrated in Chief Science Officer — donation + market sale

Greg Sorensen (CSO) sold 15,000 shares in open-market transactions and donated 7,000 shares as a charitable contribution (Form 4, ~March 2026). Other Form 4 filings in March 2026 show award grants (20,667 shares to an EVP on 2026-03-05; 22,045 to an officer on 2026-03-07) — routine equity comp, not buying. No notable open-market insider purchases surfaced. Source: stocktitan Form 4.

7. Institutional rotation is mixed — some funds cutting 30–46% stakes in Q3 2025

Victory Capital cut 46.3%, Roubaix Capital cut 43.4%, Ensign Peak cut 33.8% — all in Q3 2025 filings. Bessemer Group added 18.4%. Nations Financial initiated a small position (15,674 shares, April 2026). Total institutional ownership is 77.90%. Largest holders remain BlackRock, Vanguard, RTW Investments, Beck Mack & Oliver, T. Rowe Price. The pattern reads as small-mid fund reduction into a momentum stock that peaked in November.

8. AI-modality volume mix is the operational story

Per Q3 2025 transcript: PSMA (prostate) is now 12% of PET/CT volume, amyloid brain studies 8% — together 20% of all PET/CT procedures. Q4 2025: 14.1% aggregate / 9.6% same-center advanced imaging procedural volume growth. This is the organic engine underneath the headline — advanced imaging mix shift is doing the heavy lifting on EBITDA margin expansion (Q4 '25 margin +29 bps YoY).

9. Northwest Radiology — first center in Indiana (Feb 3, 2026)

Small tuck-in geographically significant: RadNet historically concentrated in CA/DE/MD/NJ/NY/AZ. Indiana is a new state. The tuck-in M&A cadence continues alongside the AI strategy — RadNet is doing both playbooks simultaneously.

10. Competitive framing — Quest Diagnostics peer analysis

A public comparison (artificall.com, Jan 2026) concluded: "Neither currently demonstrates a strong competitive advantage based on ROIC versus WACC analysis" for RDNT vs DGX. RDNT's current ratio 2.12 (liquidity strong), but net profit margin only 0.15%. This is consistent with the Q3 EPS miss finding — the business generates EBITDA and FCF, but GAAP profitability is thin and ROIC doesn't clearly clear WACC.

Recent News Timeline

What the Specialists Asked

Insider Spotlight

Howard G. Berger, M.D. — Chairman, President, CEO

• CEO since 1987 (38.75-year tenure); co-founder
• 2025 compensation: $12,087,934 (+24.9% YoY from $9,076,437 in 2024) — DEF14A filed 2026-04-20
• Pay mix: 33.1% salary, 66.9% bonus/equity
• Direct ownership: 0.26% of company
• Governance: Combined Chair/CEO role; ISS score 6/10

Mark D. Stolper — EVP & CFO

• Long-tenure CFO; consistently cited across earnings transcripts back to 2019
• Handled April 2024 refinancing and 2021 refinancing of senior secured term loan

Greg Sorensen, M.D. — Chief Science Officer (expanded role Jan 2026)

• Sold 15,000 shares + donated 7,000 shares (~March 2026, Form 4)
• Role expanded in January 2026 reshuffle; central to Digital Health thesis

Kees Wesdorp — President & CEO, Digital Health (appt. July 2025)

• Holds 73,825 RadNet shares post-grant
• Recruited to run DeepHealth division as standalone P&L

Stephen M. Forthuber / Norman R. Hames — Regional Presidents & CEOs (new titles Jan 2026)

• Previously COOs of East and West. Now full President & CEO titles on their regions — the most concrete succession signal available.

Industry Context

Advanced imaging modality mix shift is the defining industry trend for outpatient imaging in 2025–2026. Per Q3 2025 earnings call:

• PSMA (prostate PET/CT) is now 12% of PET/CT volume — a growth modality tied to prostate cancer diagnostics
• Amyloid brain studies represent 8% of PET/CT volume — an Alzheimer's diagnostic that became reimbursed broadly as anti-amyloid therapies (lecanemab, donanemab) entered practice
• Combined: ~20% of all PET/CT procedures are in these higher-reimbursement modalities

EBCD (Enhanced Breast Cancer Detection) adoption — blended national adoption >45%, with some large California capitated groups now paying directly for it. This is RadNet's AI-to-reimbursement linkage in action.

Payor dynamics — Q3 2025 call: "Progress converting capitated contracts to higher-paying fee-for-service" + "rate increases from many of the larger commercial and capitated payors." Payor mix shift is a quiet tailwind.

Competitive structure — RadNet operates 407 centers (Reuters) to ~9,000+ employees (LinkedIn). The only direct public comp is Quest Diagnostics (much larger, broader lab+imaging), with Akumin (private/restructured) as a distant number-two in pure-play outpatient imaging.

Hiring geography — Indeed job boards show active hiring in California (405 openings), New York/Brooklyn (304), Maryland (54), and remote (15). Roles concentrated in technologist / technician / site supervisor / medical receptionist categories — consistent with de novo center expansion rather than corporate build-out.